Active	Status	Sponsor type	Region	Phase	Filter
1 Active 1 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « August » « 2025 » M T W T F S S 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31   - « August » « 2025 » M T W T F S S 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
XmAb968 / Xencor
PRO00041908, NCT05038644: XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia	Terminated	1	22	US	XmAb18968 - Dose level -1, XmAb18968 - Dose level 0 (starting dose), XmAb18968 - Dose level 1, XmAb18968 - Dose level 2, XmAb18968 - Dose level 3	Ehab L Atallah	Acute Myeloid Leukemia, T Cell Acute Lymphoblastic Leukemia, T Cell Lymphoblastic Lymphoma	04/24	11/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
XmAb968 / Xencor
PRO00041908, NCT05038644: XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia	Terminated	1	22	US	XmAb18968 - Dose level -1, XmAb18968 - Dose level 0 (starting dose), XmAb18968 - Dose level 1, XmAb18968 - Dose level 2, XmAb18968 - Dose level 3	Ehab L Atallah	Acute Myeloid Leukemia, T Cell Acute Lymphoblastic Leukemia, T Cell Lymphoblastic Lymphoma	04/24	11/24